RemeGen Co., Ltd. announced that it has received an ethical approval from the Human Research Ethics Committee in Australia for the Phase I clinical trial of the antibody drug conjugate (ADC) RC118. The Company will initiate the Phase I clinical trial in Claudin18.2 positive patients with locally advanced unresectable or metastatic solid tumors. It is the fourth ADC product developed by the Company, which entered into clinical stage. There has been significant progress in the global ADC market in recent years, with a number of ADC products having shown promising potentials in several types of solid tumors. RC118 is another important ADC product, the company has developed after RC48 (Disitamab Vedotin), RC88 and RC108 as the Company continues to invest in and build promising ADC product pipelines.